The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.
about
Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cellsShepherding AKT and androgen receptor by Ack1 tyrosine kinaseSmall carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcriptionHepatitis C Virus Core Protein Augments Androgen Receptor-Mediated SignalingCentral role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancerTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayC/EBPalpha redirects androgen receptor signaling through a unique bimodal interactionAndrogen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH.New developments in the medical management of prostate cancer.Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells.Phosphorylation and activation of androgen receptor by Aurora-AProlonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directionsDU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation.p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements.Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells.ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatmentA hexane fraction of guava Leaves (Psidium guajava L.) induces anticancer activity by suppressing AKT/mammalian target of rapamycin/ribosomal p70 S6 kinase in human prostate cancer cellsTargeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancerImproving the outcome of patients with castration-resistant prostate cancer through rational drug development.Androgen receptor and prostate cancer.Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cellsChimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cellsRegulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.Mathematical modelling of prostate cancer growth and its application to hormone therapy.Androgen action and metabolism in prostate cancer.Molecular pathology and prostate cancer therapeutics: from biology to bedside.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Evolution of androgen receptor targeted therapy for advanced prostate cancer.Presence of Androgen Receptor Variant in Neuronal Lipid Rafts.Co-targeting androgen receptor and DNA for imaging and molecular radiotherapy of prostate cancer: in vitro studies.Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells.
P2860
Q24308733-B3E87923-09F7-4EEE-9C47-04B7E855C85EQ24308859-7EED5CCE-082A-4017-B174-1FB2B4D3FF3CQ24337882-89AB39AB-E47C-446F-9D0B-A2CA3989AF0DQ27487140-A9D3B4CA-BD1B-4425-ACCB-46BFF7BA250DQ28261485-0749F6A3-627D-4E1F-BB23-FDC7750BFC0FQ28382812-3179E289-4E9E-4852-964A-561BCFBDB6D1Q30446961-7170E152-F0C3-431B-B712-2C2CCD0AC093Q30482634-F270EE05-A26F-4805-A056-EFC8A2A278E9Q33294835-8B59E181-853C-47F7-8016-FAA27CAF17F4Q33566738-4CF39B61-182B-4275-8D0D-936A2059062DQ34012237-B32BAC4C-9F4B-4BEB-A3EF-963057C7B884Q34074062-8B66AFC0-03A5-40A5-A4A7-ECBBE2CF1D71Q34236635-ED740663-FD4C-4892-B109-F7AB47C82134Q34250227-D879A325-F6B9-4783-9933-485D17379E2DQ34324736-245E780A-51DD-45C1-81E4-40AE11236751Q34507943-599CED65-6696-4DEA-AFDF-5107E961416FQ34562695-D48D70B4-B133-4D2D-B8ED-DA7726A0BFFFQ34712118-63419E4B-8897-422C-B314-4172C37504B6Q34943321-B78FFDBD-6E6D-4BB0-AEA6-F5CD4FB11B6CQ34985562-73FCF264-CF76-4585-830A-36406108E55FQ35127176-F3E4E17A-58A7-4B4A-A856-EF3C36B2C0FCQ35542942-2F57947D-53DC-4BA9-ACE1-4594A028A5CEQ35744695-569C588C-39FC-45A7-88BA-083E090A1670Q35765678-156328FF-10AF-4771-84F1-E62DBD399778Q35962274-3AC64420-DDF6-43DF-AF11-74829FC0FD05Q36298306-4666781C-6E35-4C46-8422-FFF136A3D09FQ36597347-0449EFD4-DA49-46B6-B925-42E96639E0DDQ36734752-C8B21789-44D6-4759-BF4A-628975B71843Q36924212-C53D3F6D-2486-4316-8485-3D5EDC6BBA3CQ37074738-E5B1B50D-5063-43EE-BC12-0FE739450660Q37221646-C1BED91D-43D7-4745-A0EE-8ACFB1F2311CQ37724378-AFDB27BF-29BD-4D77-9B42-54AF6DA5AAB3Q37797777-2BDDCCC8-ED2F-4E26-B1F6-758B48094DA9Q37997571-9A8BAFCF-DC2F-4559-AAE5-C450A18688BBQ38151036-72DB2A8A-D6DD-4004-B73A-8CF3E794D9D7Q38184622-9372EE42-E106-41BF-82FC-E4F945B21ABBQ38212716-AFFCAC89-2703-4FEE-945F-2958FA58A2EEQ38693739-BA625BC5-ECF1-476A-BD23-E48CBE29010CQ38957279-2FFDF8DD-5EA0-4F8C-961D-FA3DF1A3F0DBQ39337946-0BA5D692-765F-4B9A-A56C-0412F5D2FF5C
P2860
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The androgen receptor and sign ...... ions to the androgen receptor.
@ast
The androgen receptor and sign ...... ions to the androgen receptor.
@en
type
label
The androgen receptor and sign ...... ions to the androgen receptor.
@ast
The androgen receptor and sign ...... ions to the androgen receptor.
@en
prefLabel
The androgen receptor and sign ...... ions to the androgen receptor.
@ast
The androgen receptor and sign ...... ions to the androgen receptor.
@en
P2860
P1433
P1476
The androgen receptor and sign ...... tions to the androgen receptor
@en
P2093
John M S Bartlett
P2860
P304
P356
10.1111/J.1464-410X.2005.05526.X
P577
2005-06-01T00:00:00Z